No abstract

The aim of the investigation is a determination of diagnostic value of whole blood low-frequency piezoelectric hemocoagulography method (LPH) and its suitability for monitoring the homeostasis functional state during the burn shock. 40 patients with the severe thermal injury and different consequences of burn disease have been examined in development dynamics and intensive burn shock therapy with LPH method and general biochemical tests that reflected the state of vascular platelet and coagulation homeostasis and fibrinolysis components. It has been found that severe burn shock development has been accompanied by significant pathological changes in all hemostasis sections, the rate and severity of which has been connected closely with the outcome of the burn disease. The LPH method is the easiest and most informative one for monitoring the functional states of all hemostasis sections during the dynamic critical state, such as the burn shock.

hypertension and biventricular heart failure. 53% were male. Patients ranged in age from 4 days to 18 months (mean age 5.3 months). 93% patients had at least 1 VTE associated with a central venous line (CVL) detected by ultrasound, with 1 patient developing thrombus in a BT shunt. 46.7% had >1 location with VTE. 78.6% had percutaneous CVLs, with line tip not within vena cava in 63.6%. Mean number of days from central line insertion to thrombus discovery was 8.6 days. 33% of patients were on heparin at time of thrombus discovery to maintain shunt patency, but none had systemic levels of heparin. General inflammatory state, line association, and surgery 200 ml/day) developed VTE. Only 2 patients were found to have a genetic prothrombotic predisposition. Conclusions: Patients with heart disease are at high risk for VTE development due to multiple risk factors; this can be particularly worrisome in single ventricle patients who rely on patent neck and chest venous connections for appropriate function of palliated cardiac shunts. These risk factors can help further develop anticoagulation protocols and VTE management for this complex population.